Profil
Christophe Quéva worked as a Director of Research & Hematology Oncology at Amgen, Inc. from 2006 to 2011.
He then worked as a Director of Biology & Translation Medicine at Gilead Sciences, Inc. from 2012 to 2015.
From 2015 to 2017, he served as the Chief Scientific Officer at iTeos Therapeutics SA. Currently, he is the Chief Scientific Officer & SVP-Research at Oncorus, Inc. Dr. Quéva holds a doctorate degree from Université De Lille.
Anciens postes connus de Christophe Quéva
| Sociétés | Poste | Fin |
|---|---|---|
| ONCORUS, INC. | Chief Tech/Sci/R&D Officer | 01/09/2022 |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Chief Tech/Sci/R&D Officer | 01/09/2017 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/07/2015 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2011 |
Formation de Christophe Quéva
| Université De Lille | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| ONCORUS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
